Characteristics of patients (pts) with muscle-invasive urothelial carcinoma (MIUC) who received adjuvant nivolumab (NIVO) or adjuvant platinum-based chemotherapy (CHEMO) in the real-world (RW) setting.

Alex Chehrazi-Raffle,Bruce A. Feinberg,William S. John,Taavy A. Miller,Emily Bland,Sarah Gordon,Jalyna R. Laney,Andrew J. Klink,Hedyeh Ebrahimi,Miraj Y. Patel,Lisa Rosenblatt,Carmelo Alonso,Nisha Singh,Xin Yin

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.565

IF: 45.3

2024-01-31

Journal of Clinical Oncology

Abstract:565 Background: NIVO has shown promise as an adjuvant treatment for MIUC. In the CheckMate 274 trial, NIVO achieved a significant improvement in disease-free survival compared to placebo in MIUC pts at high risk of recurrence following radical surgery. However, it is unclear how treatment decisions are made in the RW setting and what factors drive providers in selecting either NIVO or CHEMO as adjuvant treatment. We compared the baseline demographic and clinical characteristics of pts with MIUC who received adjuvant NIVO to those who received adjuvant platinum-based CHEMO in the RW setting. Methods: This retrospective medical chart review included pts diagnosed with stage II-IIIB MIUC who initiated treatment with NIVO or CHEMO within 120 days of radical resection between 9/1/2021 and 11/25/2022. Treating oncologists from a US nationally representative network abstracted pts’ data from electronic medical charts. Pts’ demographic and clinical characteristics were assessed. Results: Age, sex, and race were similar across cohorts (Table). Pts who received adjuvant NIVO (n = 158) vs CHEMO (n = 88) were more likely to have ECOG-PS≥ 2 at treatment initiation (24.1% vs 17.1%; P = 0.02), and more likely to receive PD-L1 testing (Not tested: 36.1% vs. 47.7%; P < 0.0001) and have PD-L1 expression levels ≥ 50% (13.9% vs 1.1%; P < 0.0001). A higher proportion of pts who received NIVO vs CHEMO had diabetes with chronic complications (15.8% vs 5.7%; P = 0.02) and hypertension (20.9% vs 6.8%; P = 0.004), and were determined to be cisplatin-ineligible (41.8% vs 25%; P = 0.007), predominately based on creatinine clearance (< 60 mL/min: 48.7% vs. 34.1%; P = 0.002) and poor PS (13.9% vs. 4.6%; P = 0.07); rheumatologic disease was less common among the NIVO cohort (1.9% vs 11.4%; P = 0.002). Conclusions: This RW analysis demonstrated that pts with MIUC who received adjuvant NIVO had greater baseline disease severity and comorbidities than those who received adjuvant CHEMO. These findings suggest that patient characteristics influence treatment selection of adjuvant therapy in this patient population, highlighting the need to adjust for baseline characteristics in future comparative analyses.[Table: see text]

oncology